Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9248307 | 0.93 | KCNH2 (0.54) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL5886646 | 0.92 | KCNH2 (0.55) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL5886652 | 0.90 | FFAR1 (0.63) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL9247329 | 0.87 | KCNH2 (0.51) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL5886550 | 0.83 | KCNH2 (0.59) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL5886588 | 0.82 | FFAR1 (0.53) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL11461630 | 0.81 | KCNH2 (0.45) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL1897376 | 0.81 | FFAR1 (0.55) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL6719098 | 0.81 | FFAR1 (0.55) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL12348503 | 0.81 | FFAR1 (0.55) | KCNH2FFAR1FFAR4MMP2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105707-B2 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | PHARMACORE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050137402-A1 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | DSM N.V. (NL) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137402-A1 | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds | NAT1, B3GNT2, NISCH | KCNH2 559/4885FFAR1 4642/4885FFAR4 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.